TORONTO, June 13, 2011 /CNW/ - The Ontario Institute for Cancer Research (OICR) will host a Technology Expo for the international financial community, featuring new cancer-related innovations and technologies that have emerged with the Institute's support. The event will take place on June 23, 2011 at the MaRS Centre Auditorium in Toronto, Canada.

"The Expo will provide investors with an opportunity to see first-hand some of the exciting new cancer innovations and technologies that have come out of Ontario's cancer research community," commented Frank Stonebanks, Chief Commercial Officer.  "Many of these technologies are moving to commercialization, presenting unique opportunities for life science investors."

OICR's Intellectual Property Development and Commercialization Fund (IPDC Fund) provides financial support to advance select technologies to commercialization.  IPDC Fund recipients will be present to discuss their technologies and meet one-on-one with investors.  Executives and management from OICR will also be available to provide insight into the Institute's goals and up-and-coming translational oncology programs.

Technologies and projects being featured include cancer therapeutics delivery, ultrasound therapy, high-throughput screening, and immunotherapy. Companies and institutions presenting their projects and technologies will include Harmonic Medical, Inc., DLVR Therapeutics, Inc., Privacy Analytics, Inc., TORCell Therapeutics, Inc., Xagenic, Inc., and OICR, University Health Network, and the University of Toronto.

For registration and other Expo-related information, please contact:  Tricia Swanson, at tswanson@troutgroup.com / 646-378-2953.

About OICR

OICR, based in Ontario, Canada, is an innovative cancer research and development institute dedicated to prevention, early detection, diagnosis and treatment of cancer. The Institute is an independent, not-for-profit corporation launched by the Government of Ontario in 2005. The annual budget for OICR, its research partners and collaborators exceeds $160 million. This supports more than 1,400 investigators, clinician scientists, research staff and trainees located at its headquarters and in research institutes and academia across the Province of Ontario.  It has key research efforts underway in small molecules, biologics, stem cells, imaging, genomics, informatics and bio-computing, from early stage research to Phase II clinical trials.

For more information, please visit the website at www.oicr.on.ca/commercialization.

For further information:
Rhea Cohen
Director of Communications
Email: rhea.cohen@oicr.on.ca
Telephone: 416-673-6642
Mobile: 416-671-2846